All the Therapeutic System Drugs
Ocular Antineovascularisation Agent. Aflibercept 40 mg/ml. VIAL (Sol. for Intravitreal inj.): 40 mg/ml.
Wet AMD: Initiat. tmt. 1 inj. per month
for 3 consec. doses, follow.by 1 inj.
every 2 mths. After the 1st 12 mths. of
tmt. may exten. tmt. interv. based on
vis. and anatom. outcomes. Monitor.
Sched. should be determin. by physic.
Macu. Oedem. due to CRVO: Initiat.
tmt. 1 inj. per month, follow. by 1 inj.
monthly. Diabetic Macular Oedema:
Initiat. tmt. 1 inj. per month for 5
consec. doses, follow. by 1 inj. every 2
mths. After the 1st 12 mths. of tmt. may
exten. tmt. interv. based on vis. and
Tmt. of neovasc. (wet) AMD. Tmt. of visual
impair. due to macular edem. second. to
branch RVO or central RVO. Tmt. of visual
impair. due to DME in adult.
C/I: Hypersens.; Act. or suspect. ocular or
perioc. infec.; Act. severe intraoc. inflam.
Anti-VEFG, Monoclonal Antibody. Ranibizumab 10 mg/ml. VIAL: 1 x 0.23 ml.
PFS: 1 x 0.165 ml. Initial: See lit.
Neovascular (wet) age-related macular
degen. Tmt. adults with visual impair. due
to diabet. mac. edema (DME). Tmt. visual
impair. due to macular edema second. to
retinal vein occlus. (RVO).
C/I: Hypersens., active/suspect. oc./
perioc. infects., severe intraoc. inflamm.
Antineovascularisation Agents. Verteporfin 15 mg. VIAL (Pwdr. for sol. for infus.): 1.
Photodynamic ther. (PDT) is a two-step process: The 1st step is a 10-min. IV infus. of Verteporfin at a dose of 6 mg/m² body surface area, dilute. in 30 ml infus. sol. The 2nd step is the light active. of Verteporfin at 15 min. after the start of the infus. Pts. should be re-evaluated every 3 mnths. In the event of recur. CNV leakage, The ther. may be given up to 4 times/year. See lit.
Indicated for the tmt. of pts. with predominant. classic or occult subfoveal choroidal neovascularization due to age related macular degenerat., or with subfoveal choroidal neovascularizat. caused by other macular dis.
C/I: Hypersens. Pts. with porphyria. Pts. with severe hep. impair.